HER-2 positive gastric cancer: Current targeted treatments

被引：6
作者：
Malla, Rama Rao [1 ]
Nellipudi, Haasita Reddy [2 ]
Srilatha, Mundla [3 ]
Nagaraju, Ganji Purnachandra [4 ]
机构：
[1] Gandhi Inst Technol & Management Deemed Be Univ, Canc Biol Lab, Inst Sci, Dept Biochem & Bioinformat, Visakhapatnam 530045, AP, India
[2] McMaster Univ, Sch Sci, Hamilton, ON L8S 4L8, Canada
[3] Sri Venkateswara Univ, Dept Biotechnol, Tirupati 517502, AP, India
[4] Univ Alabama Birmingham, Sch Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
来源：
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES | 2024年 / 274卷
关键词：
Gastric cancer; Metastasis; Resistance; Signaling; Adjunct therapies; TRASTUZUMAB EMTANSINE; OPEN-LABEL; GASTROESOPHAGEAL JUNCTION; PROTEIN EXPRESSION; SINGLE-ARM; ADENOCARCINOMA; ESOPHAGEAL; RESISTANCE; LAPATINIB; 1ST-LINE;
D O I：
10.1016/j.ijbiomac.2024.133247
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Gastric cancer (GC) is highly metastatic and characterized by HER2 amplification. Aberrant HER2 expression drives metastasis, therapy resistance, and tumor recurrence. HER2 amplification contributes to drug resistance by upregulating DNA repair enzymes and drug afflux proteins, reducing drug efficacy. HER2 modulates transcription factors critical for cancer stem cell properties, further impacting drug resistance. HER2 activity is influenced by HER-family ligands, promoting oncogenic signaling. These features point to HER2 as a targetable driver in GC. This review outlines recent advances in HER2-mediated mechanisms and their upstream and downstream signaling pathways in GC. Additionally, it discusses preclinical research investigation that comprehends trastuzumab-sensitizing phytochemicals, chemotherapeutics, and nanoparticles as adjunct therapies. These developments hold promise for improving outcomes and enhancing the management of HER2-positive GC.
引用
收藏
页数：9
相关论文
共 50 条
[21]   Targeted Therapy in HER2-Positive Breast Cancer [J].
Thill, Marc ;
Kraft, Clayton ;
Friedrich, Michael .
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) :295-302
[22]   Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis [J].
Lin, Yuxiang ;
Fu, Fangmeng ;
Lv, Jinxing ;
Wang, Mengchi ;
Li, Yan ;
Zhang, Jie ;
Wang, Chuan .
MEDICINE, 2020, 99 (01)
[23]   HER2-Positive Gastric Cancer [J].
Demetriades, Haralabos .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 :S190-S191
[24]   HER2-positive gastric cancer [J].
Boku, Narikazu .
GASTRIC CANCER, 2014, 17 (01) :1-12
[25]   Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer [J].
Ishii, Takahiro ;
Shitara, Kohei .
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) :1193-1201
[26]   TRKB acts as a prognostic predictive marker in Her-2 positive breast cancer [J].
Zhang, Rui ;
Zhao, Jianguo ;
Zhao, Lu .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2022, 60
[27]   HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer [J].
Inui, T. ;
Asakawa, A. ;
Morita, Y. ;
Mizuno, S. ;
Natori, T. ;
Kawaguchi, A. ;
Murakami, M. ;
Hishikawa, Y. ;
Inui, A. .
JOURNAL OF INTERNAL MEDICINE, 2006, 260 (05) :484-487
[28]   Current and Future Management of HER2-Positive Metastatic Breast Cancer [J].
Martinez-Saez, Olga ;
Prat, Aleix .
JCO ONCOLOGY PRACTICE, 2021, 17 (10) :594-+
[29]   Current status and future perspectives in HER2 positive advanced gastric cancer [J].
Roviello, G. ;
Catalano, M. ;
Iannone, L. F. ;
Marano, L. ;
Brugia, M. ;
Rossi, G. ;
Aprile, G. ;
Antonuzzo, L. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (06) :981-996
[30]   Current challenges in HER2-positive breast cancer [J].
Puglisi, Fabio ;
Fontanella, Caterina ;
Amoroso, Vito ;
Bianchi, Giulia Valeria ;
Bisagni, Giancarlo ;
Falci, Cristina ;
Fontana, Andrea ;
Generali, Daniele ;
Gianni, Lorenzo ;
Grassadonia, Antonio ;
Moscetti, Luca ;
Portarena, Ilaria ;
Rossi, Emanuela ;
Marchetti, Paolo .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 98 :211-221
12345